Cargando…
Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
Autor principal: | Park, Jung-Wee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Bone and Mineral Research
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671030/ https://www.ncbi.nlm.nih.gov/pubmed/34905681 http://dx.doi.org/10.11005/jbm.2021.28.4.339 |
Ejemplares similares
-
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
por: Kadaru, Tarun, et al.
Publicado: (2021) -
OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020) -
Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012) -
Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
por: Tutaworn, Teerapat, et al.
Publicado: (2023) -
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
por: Yamasaki, Mutsushi, et al.
Publicado: (2016)